riliprubart

News

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

News

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.